Background-High-intensity focused ultrasound (HIFU) can achieve pulmonary vein isolation (PVI), but there are safety concerns after severe complications. Therefore, we evaluated an esophageal temperature (ET)-guided safety algorithm to apply HIFU safely. Methods and Results-After standard left atrial access, HIFU was repeatedly applied until PVI was complete. A safety algorithm was used: Յ3 complete ablations per pulmonary vein (PV), early abortion when no effect after 50% of programmed time or when ET was Ն40.0°C, use of power modulation (PM) at ET 39.0°C: to reduce ablation temperature in surrounding tissue, acoustic power is switched on/off at 1 Hz; in all first ablations, use of PM after 50% of programmed time. Touch-up radiofrequency ablation was used when PVI failed. Periprocedural ET monitoring and endoscopy 2 days after ablation were performed. Twenty-eight patients (18 males; mean age at enrollment, 63 years), with paroxysmal atrial fibrillation (AF; nϭ19) and persistent AF (nϭ9) were included. In 84 of 109 PV (9 of 25 patients), PVI was achieved using HIFU only. In 9 of 109 PV, HIFU was aborted because of high ET. Mean ET at the end of the ablations with and without use of PM were 38.1Ϯ2.0°C and 37.4Ϯ1.0°C (Pϭ0.0002). During endoscopy in 2 of 26 patients, a small thermal lesion was found. Other complications included 2 persistent phrenic nerve palsies, 1 ischemic stroke, 1 pericardial effusion 48 days after ablation, 1 unexplained death 49 days after ablation, and 1 lethal atrial-to-esophageal fistula 31 days after ablation. Conclusions-The safety algorithm failed to prevent lethal complications. Currently HIFU does not meet the safety standards required for treatment of atrial fibrillation. (Circ Arrhythm Electrophysiol. 2010;3:260-265.)
C atheter ablation has been implemented in the latest guidelines as curative treatment of atrial fibrillation (AF). 1 In recent years, a novel balloon-based ablation system has been introduced and has demonstrated the potential to achieve complete electric pulmonary vein isolation (PVI) using high-intensity focused ultrasound (HIFU) (ProRhythm, Inc, Ronkonkoma, NY). 2, 3 However, there have been safety issues due to occurrence of severe and even lethal complications. 2, 4 Several parameters (defocused energy zone, reduced outer sheath diameter of 12F, esophageal temperature [ET] measurement, and use of an oversized balloon) were suggested that could possibly identify and prevent complications. 5 
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Our primary objective was to develop an ET-guided safety algorithm to apply HIFU in a safe and effective way.
Methods

Inclusion and Exclusion Criteria
This was the first study conducted with HIFU in which there was no preprocedural patient selection or imaging. Patients were considered to be not eligible for PVI when 1 or more of the following criteria were met: long-standing persistent AF (continuous AF for Ͼ1 year), a left atrial (LA) diameter Ͼ55 mm, markedly reduced left ventricular (LV) ejection fraction of Ͻ45%, severe LV hypertrophy (LV wall thickness Ͼ15 mm), LA thrombus, uncontrolled heart failure, or inability to adhere to the follow-up scheme. All patients gave written informed consent.
Preablation Investigations
One day before PVI, all patients underwent transesophageal echocardiography to determine LA diameter and LV ejection fraction, to exclude LA thrombus, and to evaluate the presence of a shunt through the interatrial septum and valve patency.
Steerable HIFU Balloon Catheter
The steerable HIFU balloon catheter (BC) consists of a noncompliant distal balloon, which is filled with a mixture of water and contrast medium and an integrated 9-MHz ultrasound crystal. Proximal, a second noncompliant balloon, filled with carbon dioxide, forms a parabolic surface at the base of the distal balloon. Thereby, ultrasound waves are reflected in forward direction, focusing a ring of ultrasound energy (sonicating ring) approximately 2 to 6 mm to the balloon surface. The HIFU BC is steerable through a pull wire mechanism integrated in the handle of the catheter and is available in balloons with a sonication ring diameter of 20 mm, 25 mm, and 30 mm, respectively. The catheter has a central lumen used for insertion of a hexapolar spiral mapping catheter (ProMap, ProRhythm, Inc) for real-time assessment of pulmonary vein (PV) potentials.
HIFU Ablation Procedure
Vital parameters were continuously monitored through the entire electrophysiological procedure. The procedure was performed under deep sedation using boluses of midazolam (0.15 mg/kg, premedication) and fentanyl (0.02 mg every 45 minutes, during ablation) as well as continuous infusion of propofol (10 mg/mL, infusion rate continuously adjusted according to level of consciousness).
After placing 6F decapolar catheters (D-type, Biosense Webster, Inc, Diamond Bar, Calif) into the coronary sinus and to the His bundle region, 2 transseptal punctures were performed using a modified Brockenbrough technique to introduce 2 8.5F sheaths (Fast-Cath SL1, St Jude Medical, Minnetonka, Minn) into the LA. Thereafter, heparin boluses were repeatedly administered to maintain the activated clotting time between 250 and 300 seconds. Selective PV angiographies were performed to identify PV ostia. A spiral catheter (Lasso, Biosense Webster, Inc) was placed at the PV ostium to record PV potentials using a conventional computerized electrophysiology system (AXIOM Sensis, Siemens, Erlangen, Germany). Pacing from the superior vena cava was then performed with maximal output (10 V, 2.9 ms) in an attempt to capture the phrenic nerve (PN).
In all study patients, an 8.5F sheath was exchanged for a steerable 12F transseptal sheath (CryoFlex, CryoCath, Montreal, Canada) to introduce the HIFU BC into the LA. After optimal ostial placement and perfect alignment with the PV axis, the proximal balloon was inflated with carbon dioxide and HIFU energy (acoustic power, 45 W) was applied for 40, 60, or 90 seconds for the balloon with the 20-mm, 25-mm, or 30-mm sonication ring, respectively.
PVI was evaluated online using the ProMap spiral catheter. Persistent acute PVI was defined as intraprocedural absence of PV potentials in the targeted PV, assessed by the Lasso spiral catheter, without evidence of reconnection by the end of the procedure. If the PV was not isolated, the HIFU BC was repositioned or exchanged for a different balloon size. The end point for ablation was the absence of PV potentials assessed by the Lasso spiral catheter.
Esophageal Temperature Monitoring
Under fluoroscopic guidance, a temperature probe with 3 sensors (Esotherm, FIAB SpA, Vicchio, Italy) was transorally advanced in the esophagus. Its position was adjusted for each ablation to position the sensors as close as possible to the ablation site.
Power Modulation Mode
Analogous to the radiofrequency current ablation catheter, where the physician has the option to lower the delivered power, a similar capability is incorporated in the HIFU ablation system. It intends to reduce temperature elevation in adjacent tissue due to conductive heat transfer. Normally, the current cycles of the HIFU ablation system deliver constant electric power, resulting in constant acoustic power output from the HIFU balloon throughout the preset ablation time. To reduce ablation temperature acoustic power is being switched on and off with a frequency of 1 Hz (power modulation).
Safety Algorithm
To decrease potential periprocedural complications due to excessive heating of adjacent tissue, a safety algorithm was developed.
If during HIFU ablation ET increased above 39.0°C or if after 20
to 30 seconds no change in PV electrograms was seen, power modulation was switched on. Previous experience with HIFU has shown that if after 20 to 30 seconds no change in PV electrograms is observed, it is less likely that the PV will be isolated during that particular sonication. 5 To prevent excessive heating of adjacent tissue, power modulation mode was switched on. 2. HIFU ablation was aborted when ET reached 40°C, also to prevent excessive heating of adjacent tissue.
3. A maximum of 3 complete HIFU ablations per PV was used. PVI is rarely completed with HIFU only if 3 full sonications failed to achieve PVI. 5
Radiofrequency Current Touch-Up Ablation
If PV potentials persisted after 3 ablations per PV, it was left to the discretion of the operator to change from HIFU to irrigated radiofrequency current ablation (RFC). An irrigated tip catheter (Celsius Thermocool, Biosense Webster, Inc) was used with a power of 30 to 40 W, a temperature limit of 43°C, and a flow-rate of 17 to 25 mL/min. Gap location and assessment of PVI were performed with a Lasso spiral catheter positioned at the respective PV ostium.
Postablation Treatment
After the end of the procedure, pericardial effusion was excluded by transthoracic echocardiography. On readmission to the ward, patients were treated with intravenous heparin. Oral anticoagulation was started the following day. All patients received phenprocoumon targeting an international normalized ratio (INR) range of 2 to 3 for at least 3 months. Two days after the ablation, an endoscopy was performed to evaluate possible presence of thermal lesions in the esophagus. In case of the presence of a thermal lesion, the endoscopy was repeated after 2 weeks. Irrespective of the maximal ET, all patients received proton pump inhibitors (pantoprazol 40 mg twice daily) for 4 weeks after the ablation. Antiarrhythmic therapy was continued for 1 month.
Statistical Analysis
Data meanϮstandard deviation (SD) was used to describe continuous variables with normal distribution; otherwise, median and range were used. For diagnostic parameters, the absolute and relative frequencies were counted. The effect of power modulation on the success of the ablation and on the esophageal temperatures was assessed using a generalized mixed model under consideration of repeated measures taken of each patient. All statistical analyses (concerning mixed modeling) were performed with Statistical Analysis System (SAS) 9.2 using the MIXED and GLIMMIX procedures.
Results
From July to December 2008, a total of 28 patients (18 male) with a mean age at enrollment of 63Ϯ7 years and a mean of 1Ϯ1 antiarrhythmic drugs used were enrolled. Nineteen patients had paroxysmal AF and 9 patients had persistent AF. The mean AF duration was 6Ϯ4 years; the median duration of the last episode of persistent AF before ablation was 4 (range, 1 to 72) months (Table 1) .
Procedural Parameters
The mean procedure time was 158Ϯ42 minutes, of which the HIFU BC remained in the LA for a mean of 71Ϯ23 minutes. The mean fluoroscopy time was 29Ϯ10 minutes.
Acute PVI
In 28 patients, 109 of 111 PVs (1 patient had a left common PV) were ablated with HIFU. In 2 right inferior PVs (RIPV) no ablation was attempted because of PN palsy that had occurred during earlier ablation of the right superior PV (RSPV). In 84 of 109 PVs (77%), persistent acute PVI was achieved exclusively using HIFU. In 25 of 28 patients (89%), all PVs were isolated at the end of the procedure. In 3 of 28 patients (11%), 1 PV could not be isolated because of failure to isolate the RIPV with touch-up RFC due to high ETs seen during HIFU application at the RIPV or due to abortion of the ablation procedure after aspiration. In 9 of 28 patients (32%), all PVs were isolated exclusively using HIFU (Figure 1) .
The mean time to PVI using HIFU was 9Ϯ5, 8Ϯ7, 13Ϯ8, and 14Ϯ12 seconds for the RSPV, RIPV, left superior PV (LSPV), and left inferior PV (LIPV), respectively.
For the isolation of 13 of 84 PVs (15%), Ͼ3 HIFU ablations were required because 11 of 13 HIFU ablations (85%) were aborted prematurely because of high ET or BC dislodgment. In 2 of 13 PVs (15%), there was reconduction after initial isolation with HIFU; these PVs were reisolated with HIFU. Maximal ET in these 13 PVs was 41.2°C. Table 2 summarizes the number of HIFU applications needed to achieve PVI.
After PVI had been achieved, a bonus application was delivered empirically in 47 of 84 PVs isolated with HIFU only (56%) to ascertain the permanency of the transmural lesion.
Touch-Up Radiofrequency Current Catheter Ablation
In a total of 25 of 111 PVs (23%) in 16 of 28 patients (57%), persistent acute PVI was achieved only after additional touch-up with RFC. Isolation failure using HIFU occurred at all PVs (5 RSPVs, 7 RIPVs, 8 LIPVs, and 5 LSPVs). Figure  2 shows the location of the conduction gaps.
Effect of Power Modulation on Acute Success of HIFU
In 191 of 311 ablations (61%) temporary PVI could be achieved using HIFU only. In 57 of 191 successful ablations (30%) power modulation was used; however, in 26 of 57 There were differences in the number of ablations needed to isolate a PV using HIFU exclusively. The majority of PVs needed 1 or 2 ablations to be isolated. For example, 8 LSPVs were isolated using only 1 HIFU ablation, and 6 LSPVs needed 2 ablations to become isolated.
isolated PVs (46%), reconduction occurred during or after ablation with power modulation switched on. The remaining 134 of 191 successful ablations were performed without use of power modulation; in this group, 49 of 134 PVs (37%) showed reconduction after the end of the ablation. This difference is statistically not significant (Pϭ0.61).
Effect of Power Modulation on Esophageal Temperature
In 77 of 311 (25%) HIFU ablations, power modulation was switched on after a median of 27Ϯ9 seconds. Mean ET at start of power modulation was 37.6Ϯ1.2°C. Mean ET at the end of the ablations with use of power modulation was 38.1Ϯ2.0°C. In contrast, mean ET at the end of the ablations without use of power modulation was 37.4Ϯ1.0°C (Pϭ0.0002).
When ET at the start of power modulation was Ͻ39.0°C, mean change in ET at the end of the ablation was ϩ0.1Ϯ0.3°C, but when ET at the start of power modulation was Ն39.0°C, mean change in ET at the end of the ablation was ϩ1.7Ϯ1.1°C (PϽ0.0001).
Endoscopy
Endoscopy was performed in 26 of 28 patients (93%). Two of 28 patients refused to undergo endoscopy but remained asymptomatic during follow-up. In 2 of 26 patients (8%) a small thermal lesion was found in the anterior part of the esophagus. Maximal ETs were 37.3°C and 41.9°C, respectively. At repeat endoscopy after 2 weeks, all thermal lesions were healed. No complaints occurred during follow-up.
Complications
Using the new 12F transseptal sheath, no major bleeding or hematoma was seen.
In 6 of 28 patients (21%), transient (nϭ4) or persistent (nϭ2) PN palsy occurred during ablation at the RSPV.
Several hours after ablation, 1 patient had a reversible ischemic neurological deficit confirmed by MRI. Symptoms resolved completely within 48 hours.
One patient had progressive dyspnea due to pericardial effusion 7 weeks after ablation. After pericardial puncture and evacuation of 1500 mL bloody fluid, the patient's condition improved significantly. Pathological and histological analysis, transesophageal echocardiography, and computed tomography did not reveal any cause for the pericardial effusion.
One 79-year-old patient was found dead in bed 49 days after ablation. Her previous medical history revealed hypertension, diabetes mellitus, obesity (body mass index, 30.9 kg/m 2 ) and nonsignificant coronary artery disease with a good LV function. The ablation procedure was uncomplicated, with a maximal ET of 36.5°C. The patient had remained asymptomatic during follow-up. No autopsy was done. No clear cause of death could be established.
Lethal Atrial-to-Esophageal Fistula
A 69-year-old patient died suddenly after 31 days of followup. His previous medical history revealed chronic obstructive pulmonary disease, obesity (body mass index, 39.4 kg/m 2 ), nonsignificant coronary artery disease, hypertension with secondary LV hypertrophy, and good LV function. During ablation of the RSPV, persistent PN palsy occurred. The procedure was completed with touch-up RFC of an anteroinferior gap in the RSPV and an anterior gap in the LSPV. Maximal ET was 39.1°C. Routine echocardiography and endoscopy did not show any abnormalities. The further clinical course was uneventful. Thirty-one days after ablation, the patient collapsed and was admitted to another hospital, where pneumonia was diagnosed. After several hours, general seizures and severe hematemesis developed suddenly. Despite resuscitation, the patient died. On autopsy, an atrialto-esophageal fistula (AEF) of 11ϫ7 mm from the posterolateral part of the LA to the distal third of the esophagus was found (Figure 3) . The pericardial fat tissue around the AEF showed extensive necrosis (Figure 4 ). In the stomach and jejunum there was 2500 mL of fresh blood. The esophagus showed no thermal or Barrett lesions. Besides the AEF, there were also signs of beginning septicemia and multiple fresh cerebral infarcts.
Discussion
We report on the largest unselected, prospective series of patients treated with HIFU for AF. Earlier studies have demonstrated high acute success rates, 5 but serious complications were also reported. 4 Therefore, we attempted to develop a safety algorithm following a distinct protocol.
The present study demonstrates that using the safety algorithm, acute PVI with HIFU ablation only could be achieved in 77% of PVs. Eight percent of PVs could not be isolated with HIFU due to excessive esophageal heating or BC dislodgment. In only 32% of patients, all PVs could be isolated using HIFU ablation only.
Although power modulation did not negatively influence acute success rates of PVI, it also did not prevent ET to exceed levels above 40.0°C at end of the ablation.
Right PN palsy has been reported to occur in Ͼ0.1% of ostial PV isolations using RFC catheter ablation and may rise up to Ͼ10% using balloon-mounted technologies. 2, 6, 7 This is due to the close proximity of the PN to the anterior part of the RSPV close to its ostium. 3, 8 PN injury with balloon technologies may stem from anatomic distortion of the PV orifice/PN relationship, through increasing contact or shortening the relative distance between the ablation site and the PN, even without displacement of the balloon into the PV. 9 Despite use of the safety algorithm and continuous PN pacing transient and persistent PN palsy occurred in 14% and 7% of patients, respectively. Even worse, use of the safety algorithm could not prevent occurrence of esophageal thermal lesions and lethal AEF.
Esophageal injury with AEF formation was observed after RFC and HIFU ablation in the LA for the treatment of AF. 4, 10 Unfortunately, to date no effective strategy has been developed to avoid esophageal injury. Although periprocedural real-time monitoring of ET is feasible, 11 recent experimental studies have demonstrated that esophageal injury can occur without detectable increase in ET. 12 In our analysis there was no relationship between maximal ET and occurrence of complications. Also, recent clinical studies showed no correlation between ET and occurrence of esophageal ulcers. 13 In fact, in 1 of the patients who had an ulcer, ET never increased above 37.3°C. We did not find a clear explanation for this finding. One can only speculate that there might be poor contact of the ET probe with the esophageal wall or that the mechanism of esophageal ulcer formation in patients treated with HIFU is independent of temperature. Significant differences between luminal ET and external esophageal tissue temperature during radiofrequency ablation of the LA have been reported. 14 Furthermore, all cases of AEF were observed at 5 to 16 days after the surgical or catheter-based procedures, suggesting that progressive tissue necrosis with lesion expansion contributed to the fistula formation. However, there are no data on the chronic changes of esophageal lesions after RFC.
The same holds true for endoscopy. During endoscopy, the luminal part of the esophagus is being inspected; the presence or absence of luminal thermal lesions is, however, no indicator for possible presence or absence of thermal damage in the outer layers of the esophagus. Also, the optimal waiting period before endoscopy should be performed is unclear. In our study we performed endoscopy after 2 days, whereas others state that most esophageal lesions are seen at day 4. 15 This diagnostic issue thus remains unresolved. After the ablation procedure, all patients received proton pump inhibitor therapy for minimally 30 days; nevertheless, this did not prevent formation of ulcers as suggested by Yokoyama et al 16 and Nakagawa et al. 17 In 1 patient, lethal AEF occurred. Endoscopy performed 2 days after the procedure revealed no thermal lesions. Histological examination of the fatty tissue between LA and esophagus showed extensive necrosis. The development of AEF without demonstration of early endothelial injury is again raising questions about the exact pathophysiology of this complication. It could be speculated that extensive fat tissue necrosis caused and/or sustained fistula formation. Our current efforts to prevent this complication are still unsatisfactory.
PVI with HIFU has proven to be successful but is not yet safe for everyday clinical use. As long as we do not understand the pathophysiology of AEF formation using HIFU we will not be able to develop an appropriate safety algorithm. Therefore, application of HIFU energy for PVI in humans cannot be advised at this point in time. Still, the concept of the energy source and mode of energy delivery may be very interesting for future treatment of AF. With mean PVI times of less than 15 seconds and a high number of complications, it is evident that the present energy source is too powerful in some patients. Furthermore, energy delivery is not titratable enough.
Conclusions
Implementation of a safety algorithm with ET-guided use of power modulation for HIFU-based PVI failed to decrease complication rates. A cutoff ET of 40.0°C does not prevent thermal damage. The problem of PN palsy and AEF occurrence remains unresolved. This issue must be resolved before HIFU can meet the safety standards required for the treatment of AF.
